64th ASH Annual Meeting and Exposition: 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Innovations in Prognostication for Patients with Acute Myeloid Leukemia

Symposia: Acute Myeloid Leukemias: Clinical and Epidemiological Oral and Poster Abstracts
Oral

Research, clinical trials, Acute Myeloid Malignancies, AML, adult, epidemiology, Clinical Practice (Health Services and Quality), Non-Biological therapies, Clinical Research, health outcomes research, Combination therapy, Chemotherapy, Diseases, Therapies, real-world evidence, Myeloid Malignancies, Study Population, Human, Minimal Residual Disease

208-210 (Ernest N. Morial Convention Center)

Moderators:

Guru Subramanian Guru Murthy, MBBS, Medical College of Wisconsin and Gina Keiffer, MD, Thomas Jefferson University

Disclosures:

No relevant conflicts of interest to declare.

This session includes studies that examine innovations in prognostication, risk factor analysis, and clinical trial design for patients with acute myeloid leukemia.

9:30 AM

Bayesian Inference for Optimization of Interim Analysis in Clinical Trials By Incorporation of Historical Data: Reanalysis of the HOVON AML 132 Clinical Trial

Niek Van Der Maas, MSc¹^*, Kazem Nasserinejad, PhD¹^*, Thomas Pabst, MD^2,3, Johan A. Maertens, MD, PhD⁴^*, Dimitri A. Breems, MD, PhD⁵, Markus G Manz^3,6, Jacqueline Cloos, Prof⁷^*, Gert J. Ossenkoppele, MD, PhD⁸, Yngvar Floisand, MD, PhD⁹^*, Patrycja Gradowska, MSc¹^*, Bob Lowenberg, MD, PhD¹⁰, Gerwin A. Huls, MD, PhD¹¹, Douwe Postmus, PhD¹¹^*, Francesco Pignatti, MD¹²^*, Jan J. Cornelissen, MD, PhD¹ and Jurjen Versluis, MD, PhD¹^*

¹Erasmus University Medical Center Cancer Institute, Rotterdam, Netherlands
²University Hospital Bern, Inselspital, Bern, Switzerland
³Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
⁴University Hospital Gasthuisberg, Leuven, Belgium
⁵Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium
⁶University Hospital Zurich, Zurich, Switzerland
⁷Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands
⁸Amsterdam Vrije Universiteit Medical Center, Amsterdam, Netherlands
⁹Oslo University Hospital, Oslo, Norway
¹⁰Erasmus University Medical Center, Rotterdam, Netherlands
¹¹University Medical Center, University Groningen, Groningen, Netherlands
¹²Oncology and Hematology Office, European Medicines Agency, Amsterdam, Netherlands

9:45 AM

Prognostic Relevance of Adult Acute Myeloid Leukemia Patients According to the 2022 European Leukemianet Risk Stratiﬁcation

Min Yen Lo, MD^1,2,3^*, Cheng-Hong Tsai, MD, PhD¹^*, Yuan-Yeh Kuo, PhD⁴^*, Mei-Hsuan Tseng, M.Sc.¹^*, Yen-Ling Peng, M.Sc.¹^*, Cheng-An Hsu⁵^*, Hsun-I Sun⁴^*, Yi-Kuang Chuang⁴^*, Wen-Chien Chou, MD, PhD^1,5, Hsin-An Hou, MD, PhD¹ and Hwei-Fang Tien, MD, PhD¹

¹Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
²Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan
³Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
⁴Tai-Cheng Stem Cell Therapy Center, National Taiwan University, Taipei, Taiwan
⁵Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan

10:00 AM

Time-Dependent Prediction of Relapse in Patients with Acute Myeloid Leukemia

John J. Lim, MD¹^*, Megan Othus, PhD², Carole M. Shaw, BA³^*, Kathryn Russell, ARNP⁴^*, Anna B. Halpern, MD⁵, Jacob S. Appelbaum, MD, PhD⁶, Roland B. Walter, MD, PhD, MS⁷ and Mary-Elizabeth M. Percival, MD⁸

¹University of Washington Medical Center, Seattle, WA
²Department of Biostatistics, University of Washington School of Public Health, Seattle, WA
³Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
⁴Fred Hutchinson Cancer Center, Seattle, WA
⁵Department of Medicine, University of Washington, Seattle, WA
⁶Department of Medicine, Division of Hematology, Seattle, WA
⁷Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
⁸Division of Hematology, Department of Medicine, University of Washington, Seattle, WA

10:15 AM

Gemtuzumab Ozogamicin Plus Standard Induction Chemotherapy Improves Outcomes in Intermediate Risk Cytogenetic Acute Myeloid Leukemia

Hassan Awada, MD¹^*, Mina Abdelmalek, MD²^*, Tara L. Cronin, BA³^*, Jeffrey Baron, PharmD⁴, Zakariya Kashour, MD²^*, Farhan Azad, MD²^*, Muhammad Salman Faisal, MD³^*, Mark G. Faber, DO⁵, Arya Roy, MD³^*, Ashish Gupta, MD³^*, Matthew Gravina, MD³^*, Sheeba Ba Aqeel, MD⁶, Alankrita Taneja, MBBS⁷, Pamela J. Sung, MD³, Steven D. Green, MD³^*, Amanda Przespolewski, DO⁶^*, James E. Thompson, MD³, Elizabeth A. Griffiths, MD⁷ and Eunice S. Wang, MD³

¹Department of Medicine, Leukemia Service,, Roswell Park Comprehensive Cancer Center, Buffalo, NY
²Department of Medicine, State University of New York at Buffalo, Buffalo, NY
³Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
⁴Department of Pharmacy, Roswell Park Comprehensive Cancer Center, Buffalo, NY
⁵Department of Medicine, Leukemia Service, Roswell Park Comprehensive Cancer Center, Buffalo, NY
⁶Department of Hematology and Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY
⁷Roswell Park Comprehensive Cancer Center, Buffalo, NY

10:30 AM

The Addition of Venetoclax to Induction Chemotherapy in No Low-Risk AML Patients: A Propensity Score-Matched Analysis of the Gimema AML1718 and AML1310 Trials

Alfonso Piciocchi, MS¹^*, Monica Messina¹^*, Marta Cipriani¹^*, Francesca Paoloni¹^*, Giorgia Simonetti, PhD²^*, Raffaele Palmieri, MD³^*, Giovanni Marconi, MD⁴, Francesco Buccisano, MD³, Paola Fazi, MD¹^*, Marco Vignetti, MD^1,5^*, Giovanni Martinelli, MD⁶ and Adriano Venditti, MD⁷

¹GIMEMA Foundation, Rome, Italy
²Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
³Hematology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
⁴IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy
⁵Dept of Cellular Biotechnologies and Hematology, University "la Sapienza", Roma, Italy
⁶IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy
⁷Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy

10:45 AM

Prognostic Impact of Day 14 Bone Marrow (D14 BM Bx) in Acute Myeloid Leukemia (AML) in the Setting of European Leukemianet (ELN) Risk Classification

Metodi Balev, MD¹^*, Nicole Zubizarreta¹^*, Erin Bresnahan, MD¹^*, Jonathan Feld, MD¹, Marina Kremyanskaya, MD, PhD¹, Alla Keyzner, MD², Alan H. Shih, MD, PhD², Bridget K Marcellino, MD, PhD³, Lewis R. Silverman, MD², Michal Bar-Natan, MD², John Mascarenhas, MD¹ and Douglas Tremblay, MD²

¹Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
²Tisch Cancer Institute, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
³Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

613.O4.6 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Innovations in Prognostication for Patients with Acute Myeloid Leukemia